Utrobin (Solifenacin): An Antimuscarinic Agent for Overactive Bladder

Utrobin contains Solifenacin, a competitive muscarinic receptor antagonist. It is indicated for the symptomatic treatment of an overactive bladder, which includes symptoms of urge incontinence, increased urinary frequency, and urgency. It works by blocking the receptors that cause bladder muscle contractions. Utrobin belongs to the therapeutic class of Anticholinergics and BPH/Urinary retention/Urinary incontinence drugs.

How Utrobin Works (Pharmacology)

Solifenacin's primary function is to block muscarinic receptors in the bladder:

• Muscarinic Receptor Antagonist: It is a competitive antagonist with the highest affinity for M3, M1, and M2 muscarinic receptors.
• Prevents Bladder Contraction: By antagonizing the M3 receptor, it prevents the contraction of the detrusor muscle, which is the main muscle of the bladder. Antagonism of the M2 receptor may also help prevent smooth muscle contraction.
• Reduces Symptoms: This action helps to control the involuntary bladder contractions that cause the symptoms of overactive bladder, such as urgency, frequency, and incontinence.

Key Indications & Benefits

Utrobin is indicated for the symptomatic treatment of an overactive bladder with:

• Urge incontinence.
• Increased urinary frequency.
• Urgency.

Dosage & Administration

Utrobin is for adults and the elderly. It is taken once daily and can be taken with or without food. The tablet should be swallowed whole with liquids. Always consult a registered physician for specific dosage instructions.

• Adults and elderly: The recommended starting dose is 5 mg once daily.
• Increased dose: If needed, the dose may be increased to 10 mg once daily.
• Children: Safety and effectiveness have not been established, and it should not be used in children.

Important Considerations & Warnings

It is crucial to discuss your full medical history with your doctor before taking Utrobin.

Contraindications:

• Hypersensitivity to solifenacin or any excipients.
• Myasthenia gravis.
• Urinary retention.
• Uncontrolled narrow-angle glaucoma.
• Severe gastrointestinal conditions (e.g., toxic megacolon).
• Severe hepatic impairment.
• Severe renal impairment or moderate hepatic impairment while also on a strong CYP3A4 inhibitor.
• Patients undergoing haemodialysis.

Side Effects:

• Most common: Dry mouth (the most frequently reported side effect), constipation, nausea, abdominal pain, and blurred vision.
• Other common side effects: Urinary tract infection, cystitis, somnolence, dizziness, dry eyes, and fatigue.
• Rare/Serious: Urinary retention, colonic obstruction, hallucinations, and allergic reactions (pruritus, rash, urticaria).

Pregnancy & Lactation:

• Pregnancy: There are no clinical studies in pregnant women. Caution should be exercised, and it should only be used if clearly needed.
• Lactation: It is unknown if solifenacin is excreted in human milk. Its use should be avoided during breast-feeding.

Precautions & Warnings:

• Bladder Outflow Obstruction: Use with caution in patients with bladder outflow obstruction due to the risk of urinary retention.
• Gastrointestinal Disorders: Use with caution in patients with gastrointestinal obstructive disorders or a risk of decreased gastrointestinal motility.
• Renal and Hepatic Impairment: Use with caution and at a lower dose (maximum 5 mg daily) in patients with severe renal impairment or moderate hepatic impairment.
• Drug Interactions: The maximum dose should be limited to 5 mg when used with potent CYP3A4 inhibitors (e.g., Ketoconazole, Ritonavir).
• Driving and Machinery: Utrobin may cause blurred vision, drowsiness, and fatigue, which can negatively affect the ability to drive or operate machinery.

Drug Interactions:

• Anticholinergic drugs: Concomitant use may increase therapeutic and adverse effects.
• Cholinergic receptor agonists: May reduce the therapeutic effect of Utrobin.
• GI motility drugs (e.g., Metoclopramide, Cisapride): Utrobin can reduce their effect.
• Potent CYP3A4 inhibitors (e.g., Ketoconazole, Ritonavir): These can significantly increase the concentration of Solifenacin in the blood.

Overdose Effects

• An overdose can cause severe anticholinergic effects.
• Treatment is symptomatic and supportive, including activated charcoal and, in some cases, specific medications like physostigmine for severe effects.

Storage Conditions

Store in a cool and dry place, protected from light.